Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05199792 · ClinicalTrials.gov registry record
Efficacy of Gadoterate Meglumine in Diagnosis of Vascular Diseases Using MRA MRA
A clinical trial, sponsored by Northwestern University.
- Completed
- Registry status
- 65
- Enrollment target
NCT05199792: Completed study, sponsored by Northwestern University.
NCT05199792 is a clinical trial that has completed, run by Northwestern University. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05199792 has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to compare magnetic resonance angiography (MRA) using gadoterate meglumine to clinically obtained MRA using gadobutrol. The specific aims are to show: 1. Carotid, chest, and abdomenal MRA with gadoterate meglumine has a comparable image quality and diagnostic confidence to MRA using gadobutrol. 2. Carotid, chest, and abdomenal MRA with gadoterate meglumine has a comparable accuracy for vascular lesion and stenosis detection compared to MRA using gadobutrol.
Primary Outcome
assess the image quality of MRA studies acquired using these two contrast
Interventions
- DIAGNOSTIC_TEST Dotarem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2017-06-02 |
| Est. Completion | 2020-01-01 |
What the finished NCT05199792 record still lists
NCT05199792 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Dotarem is the first listed.
NCT05199792 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05199792 about?
NCT05199792 is a clinical study titled "Efficacy of Gadoterate Meglumine in Diagnosis of Vascular Diseases Using MRA MRA". The purpose of this study is to compare magnetic resonance angiography (MRA) using gadoterate meglumine to clinically obtained MRA using gadobutrol. The specific aims are to show: 1. Carotid, chest, and abdomenal MRA with gadoterate meglumine has a comparable image quality and diagnostic confidence...
What is the current status of trial NCT05199792?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2017-06-02. Estimated completion is 2020-01-01.
What interventions are being tested in trial NCT05199792?
The interventions under investigation include: Dotarem (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05199792?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI